

# Swaminathan Padmanabhan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3183770/swaminathan-padmanabhan-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153 papers	5,448 citations	37 h-index	72 g-index
167 ext. papers	6,476 ext. citations	4.5 avg, IF	5.06 L-index

#	Paper	IF	Citations
153	Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤5 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.. <i>Lancet Oncology, The</i> , <b>2022</b> ,	21.7	3
152	Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis: A brief case report.. <i>Leukemia Research Reports</i> , <b>2022</b> , 17, 100292	0.6	0
151	Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy.. <i>Blood Advances</i> , <b>2022</b> ,	7.8	2
150	An improved index for diagnosis and mortality prediction in malignancy associated hemophagocytic lymphohistiocytosis. <i>Blood</i> , <b>2021</b> ,	2.2	8
149	Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , <b>2021</b> , 138, 133-133	2.2	3
148	No Difference in Survival Among Black Patients with Mycosis Fungoides and Sclary Syndrome: A Multicenter Retrospective Analysis. <i>Blood</i> , <b>2021</b> , 138, 2441-2441	2.2	
147	Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. <i>Blood</i> , <b>2021</b> , 138, 1740-1740	2.2	
146	The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 135-135	2.2	1
145	Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. <i>Blood</i> , <b>2021</b> , 138, 3525-3525	2.2	2
144	Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. <i>Blood</i> , <b>2021</b> , 138, 3870-3870	2.2	
143	A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 38-38	2.2	
142	CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. <i>Blood</i> , <b>2021</b> , 138, 3560-3560	2.2	0
141	Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study. <i>Blood</i> , <b>2021</b> , 138, 1365-1365	2.2	0
140	Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. <i>Modern Pathology</i> , <b>2021</b> ,	9.8	1
139	Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma. <i>Annals of Hematology</i> , <b>2021</b> , 1	3	0
138	Targeted based therapy in nodal T-cell lymphomas. <i>Leukemia</i> , <b>2021</b> , 35, 956-967	10.7	2
137	Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. <i>British Journal of Haematology</i> , <b>2021</b> , 193, e23-e26	4.5	2

136	Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. <i>Modern Pathology</i> , <b>2021</b> , 34, 2148-2153	9.8	2
135	Global Ophthalmology Practice Patterns during COVID-19 Pandemic and Lockdown. <i>Ophthalmic Epidemiology</i> , <b>2021</b> , 1-12	1.9	3
134	Gamma/Delta Phenotype in Primary Cutaneous T-cell Lymphomas and Lymphoid Proliferations: Challenges for Diagnosis and Classification. <i>Surgical Pathology Clinics</i> , <b>2021</b> , 14, 177-194	3.9	3
133	Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. <i>Modern Pathology</i> , <b>2021</b> , 34, 2154-2167	9.8	6
132	Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement. <i>British Journal of Haematology</i> , <b>2021</b> , 192, e17-e21	4.5	1
131	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. <i>Human Pathology</i> , <b>2021</b> , 108, 22-31	3.7	3
130	Safety of CAR T-cell therapy in kidney transplant recipients. <i>Blood</i> , <b>2021</b> , 137, 2558-2562	2.2	7
129	G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?. <i>Annals of Hematology</i> , <b>2021</b> , 100, 667-673	3	6
128	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. <i>Blood</i> , <b>2021</b> , 137, 3272-3276	2.2	29
127	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. <i>Blood Advances</i> , <b>2021</b> , 5, 2799-2806	7.8	6
126	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. <i>ESMO Open</i> , <b>2021</b> , 6, 100172	6	0
125	Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 201-209	4.5	5
124	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5847-5856	12.9	0
123	BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 153	7	0
122	Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. <i>JAAD Case Reports</i> , <b>2021</b> , 17, 34-37	1.4	
121	The impact of cell-of-origin, MYC/Bcl-2 dual expression and rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1361-1369	1.9	0
120	The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, Deletion, and a Poor Prognosis.. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
119	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. <i>JAAD Case Reports</i> , <b>2020</b> , 6, 1264-1267	1.4	2

118	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. <i>JAMA Network Open</i> , 2020, 3, e2013935	10.4	3
117	T-cell lymphoma secondary to checkpoint inhibitor therapy 2020, 8,		13
116	Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1965-1973	1.9	6
115	SARS-CoV-2 in multiple myeloma: initial observation and management. <i>Leukemia and Lymphoma</i> , 2020, 61, 2763-2766	1.9	1
114	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2871-2883	7.8	48
113	Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 621-626	3.5	4
112	Pretreatment SUV may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. <i>Leukemia and Lymphoma</i> , 2020, 61, 1380-1387	1.9	2
111	CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. <i>Human Pathology</i> , 2020, 98, 1-9	3.7	6
110	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629	7.1	26
109	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 3546-3556	12.9	4
108	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 17-18	2.2	
107	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 17-18	2.2	
106	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 34-35	2.2	
105	Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. <i>Blood</i> , 2020, 136, 10-12	2.2	
104	Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 27-28	2.2	1
103	A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2020, 136, 1-2	2.2	
102	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 40-41	2.2	
101	Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3030-3030	2.2	5

100	Demand and Supply of Face Masks during the COVID-19 Pandemic. <i>Smart and Sustainable Manufacturing Systems</i> , <b>2020</b> , 4, 20200069	0.8	
99	Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Prospective Series of 52 Patients. <i>Annals of Surgery</i> , <b>2020</b> , 275,	7.8	6
98	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 665-671	4.7	7
97	Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. <i>JCO Global Oncology</i> , <b>2020</b> , 6, 1124-1133	3.7	1
96	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , <b>2020</b> , 4, 3943-3951	7.8	30
95	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. <i>ESMO Open</i> , <b>2020</b> , 5,	6	15
94	Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K $\gamma$ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	9
93	Anaplastic Large Cell Lymphoma of the Breast Arising in a Burn Cicatrix. <i>Aesthetic Surgery Journal</i> , <b>2020</b> , 40, NP159-NP163	2.4	3
92	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. <i>Modern Pathology</i> , <b>2020</b> , 33, 324-333	9.8	20
91	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. <i>Haematologica</i> , <b>2020</b> , 105, e355-e357	6.6	3
90	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 533-541	2	0
89	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , <b>2020</b> , 4, 1038-1050	7.8	25
88	Adoptive cell therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1370-1380	1.9	3
87	Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues. <i>Annals of Diagnostic Pathology</i> , <b>2019</b> , 43, 151398	2.2	
86	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2019</b> , 133, 2765-2775	2.2	42
85	Parsaclisib, a potent and highly selective PI3K $\gamma$ inhibitor, in patients with relapsed or refractory B-cell malignancies. <i>Blood</i> , <b>2019</b> , 133, 1742-1752	2.2	47
84	Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K $\gamma$ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 2831-2831	2.2	2
83	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6781-6787	12.9	3

82	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , <b>2019</b> , 3, 1356-1367	7.8	9
81	Characteristics and Treatment of Advanced Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , <b>2019</b> , 143, 41S-50S	2.7	36
80	Triple-hit lymphoma of the cavernous sinus. <i>Canadian Journal of Ophthalmology</i> , <b>2019</b> , 54, e61-e66	1.4	2
79	Acute myeloid leukemia with eosinophilia after cyclin-dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E82-E85	7.1	2
78	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 229-240	4.0	283
77	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e51-e61	2	7
76	Cross Talk between Radiation and Immunotherapy: The Twain Shall Meet. <i>Radiation Research</i> , <b>2018</b> , 189, 219-224	3.1	4
75	Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. <i>Radiation Research</i> , <b>2018</b> , 190, 322-329	3.1	25
74	Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6150-6159	12.9	20
73	SMARCA1 Phosphorylation and Ubiquitination Are Required for Resection during DNA Double-Strand Break Repair. <i>IScience</i> , <b>2018</b> , 2, 123-135	6.1	30
72	Use of PEG-asparaginase in a case of Hepatosplenic T-cell lymphoma with long-term remission after stem cell transplantation. <i>Ecancermedicalscience</i> , <b>2018</b> , 12, 872	2.7	1
71	Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. <i>Ecancermedicalscience</i> , <b>2018</b> , 12, 836	2.7	6
70	Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1-11	1.9	14
69	Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. <i>Ecancermedicalscience</i> , <b>2017</b> , 11, 771	2.7	10
68	Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. <i>Hematological Oncology</i> , <b>2017</b> , 35, 914-917	1.3	33
67	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. <i>Oncotarget</i> , <b>2017</b> , 8, 41620-41630 <sup>o</sup>	3.3	1630 <sup>o</sup>
66	Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 868-76	12.9	199
65	A unique aptamer-drug conjugate for targeted therapy of multiple myeloma. <i>Leukemia</i> , <b>2016</b> , 30, 987-910.7	10.7	37



64	HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. <i>Leukemia</i> , <b>2016</b> , 30, 504-8	10.7	30
63	Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML. <i>Blood</i> , <b>2016</b> , 128, 3983-3983	2.2	13
62	An Integer Weighted Genomic Mutation Scoring (IWGMS) Using the Trusight Myeloid Sequencing Panel (Illumina) Shows Higher Mortality in Patients with Intermediate Risk Acute Myeloid Leukemia- a Retrospective Study. <i>Blood</i> , <b>2016</b> , 128, 2889-2889	2.2	
61	Utility of $^{18}$ F-fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. <i>Annals of Oncology</i> , <b>2015</b> , 26, 774-779	10.3	14
60	Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. <i>Biomaterials</i> , <b>2015</b> , 67, 42-51	15.6	64
59	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3467-74	2.2	129
58	Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , <b>2015</b> , 121, 2185-92	6.4	38
57	Pre-clinical efficacy of combined therapy with novel $\text{E}^{\text{6}}$ atenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. <i>Leukemia</i> , <b>2015</b> , 29, 1267-78	10.7	64
56	Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. <i>Oncologist</i> , <b>2015</b> , 20, 1084-91	5.7	39
55	Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1142-54	6.1	143
54	BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 2315-27	6.1	110
53	Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. <i>Leukemia</i> , <b>2014</b> , 28, 2155-64	10.7	187
52	A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 366-75	4.5	110
51	WTAP is a novel oncogenic protein in acute myeloid leukemia. <i>Leukemia</i> , <b>2014</b> , 28, 1171-4	10.7	153
50	Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 489-99	4.3	61
49	Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 35-41	3.5	35
48	Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 897-908	3.5	55
47	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 334-42	4.5	33

46	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , <b>2012</b> , 120, 4324-33	2.2	193
45	The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor $\beta$ -related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 32875-80	5.4	16
44	Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 2693-703	7.5	43
43	Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1107-15	4.3	37
42	Targeting PIM kinase activity significantly augments the efficacy of cytarabine. <i>British Journal of Haematology</i> , <b>2012</b> , 156, 129-32	4.5	17
41	Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 631-6	2.2	452
40	A comparison of races and leukemia subtypes among patients in different cancer survivorship phases. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11 Suppl 1, S114-8	2	10
39	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 117, 6450-8	2.2	107
38	Targeting aurora kinases in cancer treatment. <i>Current Drug Targets</i> , <b>2011</b> , 12, 2067-78	3	39
37	The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. <i>Journal of Cellular and Molecular Medicine</i> , <b>2011</b> , 15, 2057-70	5.6	67
36	Mammalian target of rapamycin as a target in hematological malignancies. <i>Targeted Oncology</i> , <b>2011</b> , 6, 53-61	5	15
35	Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. <i>Cancer</i> , <b>2011</b> , 117, 2127-35	6.4	66
34	A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy. <i>Journal of Clinical Pathology</i> , <b>2011</b> , 64, 809-13	3.9	39
33	Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. <i>Blood</i> , <b>2011</b> , 118, 5126-9	2.2	139
32	Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237) An Investigational Aurora A Kinase Inhibitor In Patients with Advanced Hematologic Malignancies. <i>Blood</i> , <b>2011</b> , 118, 2477-2477	2.2	1
31	Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1422-8	2.2	118
30	Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1749-55	2.2	483
29	Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. <i>Blood</i> , <b>2010</b> , 116, 4591-9	2.2	34



28	Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. <i>Blood</i> , <b>2010</b> , 115, 3796-800	2.2	203
27	Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 670-4	7.1	104
26	Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. <i>Targeted Oncology</i> , <b>2009</b> , 4, 99-105	5	57
25	Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 297-9	1.9	
24	Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 1096-101	1.9	22
23	High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. <i>Bone Marrow Transplantation</i> , <b>2008</b> , 41, 393-8	4.4	52
22	Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , <b>2008</b> , 41, 613-9	4.4	22
21	Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 1494-500	1.9	2
20	Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature. <i>Transplant Infectious Disease</i> , <b>2007</b> , 9, 148-52	2.7	12
19	Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 1228-30	1.9	6
18	HLA-identical sibling stem-cell transplantation in first-remission AML. <i>Blood</i> , <b>2007</b> , 110, 4619; author reply 4619-20	2.2	2
17	Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2007</b> , 13, 765-70	4.7	63
16	Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities.. <i>Blood</i> , <b>2007</b> , 110, 754-754	2.2	9
15	Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5343-9	2.2	357
14	Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 2339-43	1.9	19
13	Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2006</b> , 12, 241-2	4.7	9
12	Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. <i>Blood</i> , <b>2006</b> , 107, 1970-3	2.2	22
11	Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. <i>Bone Marrow Transplantation</i> , <b>2006</b> , 37, 781-4	4.4	9

10	First Clinical Evidence of In Vivo Natural Killer (NK) Cell Modulation in Chronic Lymphocytic Leukemia (CLL) Patients (pts) Treated with Lenalidomide (L).. <i>Blood</i> , <b>2006</b> , 108, 2109-2109	2.2	5
9	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. <i>Blood</i> , <b>2006</b> , 108, 3033-3033	2.2	
8	Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma, Receiving Bisphosphonate Therapy, Is Independent of Renal Function: Single Institute Experience of an Emerging Clinical Problem.. <i>Blood</i> , <b>2006</b> , 108, 5129-5129	2.2	
7	Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 1813-8	1.9	4
6	Protein kinase C beta11 plays an essential role in dendritic cell differentiation and autoregulates its own expression. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 28412-23	5.4	37
5	Characterization of IMiDs (Immunomodulating Agents) Induced Flare Reaction in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.. <i>Blood</i> , <b>2005</b> , 106, 5049-5049	2.2	4
4	High Frequency and Early Onset of Bone Mineral Density Loss Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , <b>2005</b> , 106, 2011-2011	2.2	1
3	Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2800-7	2.2	89
2	Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. <i>Cancer Gene Therapy</i> , <b>2003</b> , 10, 850-8	5.4	25
1	Higher mortality in men from COVID19 infection-understanding the factors that drive the differences between the biological sexes		2